Centessa's mission is discovering and developing transformational orexin-focused medicines, particularly OX2R agonists for sleep-wake, neurological, neurodegenerative, and neuropsychiatric disorders.1
ORX750 showed positive Phase 2a topline data from initial low-dose cohorts in NT1, NT2, and IH patients as of September 23, 2025, with statistically significant, dose-dependent efficacy, favorable safety, and plans for registrational program in Q1 2026.1
ORX142 Phase 1 data in sleep-deprived healthy volunteers expected in 2025, with patient studies planned for Q1 2026.1
ORX489 advancing in IND-enabling studies, with clinical studies planned for Q1 2026 subject to IND clearance.1
Robust clinical milestones anticipated across the OX2R agonist pipeline in 2026, building a potential best-in-class franchise.12
Sources:
1. https://www.marketscreener.com/news/centessa-pharmaceuticals-february-2026-corporate-overview-597223-ce7e5ad2d088f722
2. https://trial.medpath.com/news/48e041810b18d01d/centessa-pharmaceuticals-advances-orexin-agonist-pipeline-with-leadership-transition-and-promising-clinical-data